Quarterly report pursuant to Section 13 or 15(d)

Note 4 - Acquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details)

v3.20.4
Note 4 - Acquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details) - USD ($)
$ in Thousands
2 Months Ended 6 Months Ended
Dec. 31, 2020
Dec. 31, 2020
Dec. 31, 2019
Oct. 20, 2020
Jun. 30, 2020
Goodwill $ 746,666 $ 746,666     $ 728,308
Cash paid, net of cash acquired   9,765 $ (0)    
Changzhou Eminence Biotechnology [Member]          
Current assets, net of cash 3,145 3,145      
Equipment and other long-term assets 1,639 1,639      
Goodwill 8,811 8,811      
Total assets acquired 22,506 22,506      
Liabilities 1,436 1,436      
Deferred income taxes, net 2,320 2,320      
Net assets acquired 18,750 18,750      
Cash paid, net of cash acquired 9,765        
Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value 8,985 8,985   $ 9,000  
Net assets acquired 18,750        
Changzhou Eminence Biotechnology [Member] | Developed Technology Rights [Member]          
Intangible assets 6,778 6,778      
Changzhou Eminence Biotechnology [Member] | Customer Relationships [Member]          
Intangible assets $ 2,133 $ 2,133